https://orcid.org/0000-0001-6594-3710
References
- Wirtz VJ, Hogerzeil HV, Gray AL, Bigdeli M, de Joncheere CP, Ewen MA, Gyansa-Lutterodt M, Jing S, Luiza VL, Mbindyo RM, et al. Essential medicines for universal health coverage. Lancet. 2017;389(10067):403–10. doi:10.1016/S0140-6736(16)31599-9.
- United Nations. Sustainable development goals. 2015 https://sustainabledevelopment.un.org/sdgs Accessed 20 February 2021.
- Clarke D, Doerr S, Hunter M, Schmets, Schmets G, Soucat A, Paviza A. The private sector and universal health coverage. Bull World Health Organ. 2019;97(6):434–35. doi:10.2471/BLT.18.225540.
- Hamidu H, Amran 8 October . Corporate Social Responsibility stages of transformation, drivers and dimensional models: a review. SSRN. 2016.
- Nations U. Report of the United Nations Secretary-General’s High-Level Panel on Access to Medicines: promoting innovation and access to health technologies [Internet]. New York (NY): UN; 2016 Sep [cited 2021 Apr 15]. Available from: http://www.unsgaccessmeds.org/final-report/
- International Federation of Pharmaceutical Manufacturers & Associations (2019). Achieving a healthier and sustainable future for all: policy perspectives on Universal Health Coverage from the innovative biopharmaceutical company. Available from: https://www.ifpma.org/wp-content/uploads/2019/09/IFPMA_Policy_Perspectives_on-_UHC_Full_Report.pdf Accessed 22 February 2021
- Rockers PC, Wirtz VJ, Umeh CA, Swamy PM, Laing RO. Industry-Led Access-To-Medicines Initiatives In Low- And Middle-Income Countries: strategies And Evidence. Health Aff. 2017; 36(4): 706–13. http://dx.doi.org.ezproxy.bu.edu/10.1377/hlthaff.2016.1213 Accessed 05 January 2021
- Rockers PC, Reich MR, Kettler H, Wirtz, VJ, et al. Commitment to Impact: strengthening Measurement of Industry-Led Access-to-Medicines Programs. Health Systems & Reform. 2018;4(3):188–93. doi:10.1080/23288604.2018.1483710.
- Droppert H, Bennet S. Corporate social responsibility in global health: an exploratory study of multinational pharmaceutical firms. Global Health. 2015:11. doi:10.1186/s12992-015-0100-5.
- Kramer MR. Creating shared value. Harv Bus Rev. 2011;Jan-Feb:62–77.
- Access Observatory. Programs. Available at: www.accessobservatory.org/programs/.
- McKinsey Global Institute (2020). Prioritizing health: a prescription for progress. Available from: https://www.mckinsey.com/industries/healthcare-systems-and-services/our-insights/prioritizing-health-a-prescription-for-prosperity Accessed 28 February 2022.
- Sruamsiri R, Wagner AK, Ross-Degnan D, Lu CY, Dhippayom T, Ngorsuraches S, Chaiyakunapruk N. Expanding access to high-cost medicines through the E2 access program in Thailand: effects on utilisation, health outcomes and cost using an interrupted time-series analysis. BMJ Open. 2016 Mar 17;6(3):e008671. doi:10.1136/bmjopen-2015-008671. PMID: 26988346.
- Conway M, Holt T, Sabow Holt T (2019). Should sub-Saharan Africa make its own drugs? What’s next for pharma in emerging markets? McKinsey & Company. https://www.mckinsey.com/industries/public-and-social-sector/our-insights/should-sub-saharan-africa-make-its-own-drugs Accessed 20 February 2022
- Brest P, Born K (2013). Unpacking the impact in impact investing. Stanford Social Innovation Review. Available at https://ssir.org/articles/entry/unpacking_the_impact_in_impact_investing.
- Rockers PC, Laing RO, Ashigbie PG, Onyango MA, Mukiira CK, Wirtz VJ. Effect of Novartis Access on availability and price of non-communicable disease medicines in Kenya: a cluster-randomised controlled trial. Lancet Global Health. 2019;7(4):e492–e502. doi:10.1016/S2214-109X(18)30563-1.
- Patel A, Praveen D, Maharani A, Oceandy D, Pilard Q, Kohli MPS, Sujarwoto S, Tampubolon G. Association of multifaceted mobile technology-enabled primary care intervention with cardiovascular disease risk management in Rural Indonesia. JAMA Cardiology. 2019;4(10):978–86. doi:10.1001/jamacardio.2019.2974.
- Umeh, Umeh CA, Rockers PC, Laing RO, Wagh O, Wirtz VJ. Pharmaceutical industry-led partnerships focused on addressing the global burden of non-communicable diseases: a review of Access Accelerated. Public Health. 2020;181:73–79. doi:10.1016/j.puhe.2019.12.008.
- Adamu SA (2017). Impact of corporate social responsibility on financial performance in the pharmaceutical industry. Theses and Dissertations. 903. https://digitalcommons.pepperdine.edu/etd/903 Accessed 13 February 2021
- Agarwal A, Dreszer J, Mina J (2017). What’s next for pharma in emerging markets? McKinsey & Company. Available at: https://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/whats-next-for-pharma-in-emerging-markets Accessed 20 February 2021
- Ascher J, Bogdan B, Dreszer J, Zhao, G, et al. (2015). Pharma’s next challenge. McKinsey & Company. https://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/pharmas-next-challenge Accessed 21 February 2021
- Umeh CA, Garcia-Gonzalez P, Tremblay D, Laing R. The survival of patients enrolled in a global direct-to-patient cancer medicine donation program: the Glivec International Patient Assistance Program (GIPAP). EClinicalMedicine. 2020:19. doi:10.1016/j.eclinm.2020.100257.
- Jones MB. The multiple sources of mission drift. Nonprofit and Voluntary Sector Quarterly. 2007;36(2):299–307. doi:10.1177/0899764007300385.
- Ebrahim A, Battilana J, Mair J. The governance of social enterprises: mission drift and accountability challenges in hybrid organizations. Research in Organizational Behavior. 2014;34:81–100. doi:10.1016/j.riob.2014.09.001.